GRAINS-BP:高纤维干预调控高血压神经信号的双盲随机交叉安慰剂对照试验
GRAINS-BP试验计划招募29例未治疗高血压成人,采用双盲交叉设计,每日两次摄入富含乙酸盐和丁酸盐的高直链玉米淀粉(HAMSA/B)奶昔,评估其对自主神经活动(主要结局)及24小时血压、肠道菌群等的影响,以验证短链脂肪酸是否经肠脑轴降低肌肉交感神经活动从而降压。
要点
- 高纤维饮食通过短链脂肪酸可能经肠脑轴降低肌肉交感神经活动而降压。
- 试验采用双盲交叉安慰剂对照设计,主要结局为自主神经系统活动变化。
- 次要结局包括24小时血压、肠道菌群组成、短链脂肪酸水平及免疫细胞谱等。
核心结论
- 该试验将揭示短链脂肪酸是否通过影响自主神经系统来降低血压。
研究设计与样本
- 双盲、随机交叉、安慰剂对照试验,计划招募29例未治疗高血压(≥140/90 mmHg)成人。
- 干预为HAMSA/B奶昔每日两次,每个干预期14天,间隔20天洗脱后交叉,评估期共48天,含4次访视。
关键数值与推荐
- 纳入标准为未治疗高血压,血压≥140/90 mmHg。
- 主要结局为自主神经系统活动变化;次要结局包括24小时血压、肠道菌群组成、短链脂肪酸水平、免疫细胞谱、胃肠转运时间、生活质量、焦虑抑郁症状、认知功能、肠道屏障完整性及循环微纳塑料。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension affects 1 in 3 Australian adults and is a major contributor to stroke and myocardial infarction. Despite the availability of various medications, over 50% of patients struggle to control their blood pressure (BP) due to nonadherence, difficulty finding the right treatment, or avoidance of medication. Diet plays a key role in cardiovascular health, with high-fiber intake shown to lower BP through the production of short-chain fatty acids (SCFAs), metabolites formed during fiber fermentation. A previous clinical trial found that incorporating a specific type of resistant starch - high amylose maize starch enriched with acetate and butyrate (HAMSA/B) - significantly reduced blood pressure in hypertensive patients. While the exact mechanism remains unclear, SCFAs may influence BP via the gut-brain axis by reducing muscle sympathetic nerve activity (MSNA), which has vasoconstrictor function and is elevated in hypertensive individuals. METHODS: The GRAINS-BP clinical trial will recruit 29 adults with untreated hypertension (≥ 140/90 mmHg) for a double-blind, cross-over study using HAMSA/B administered as a shake delivered twice daily. The assessment period will span 48 days and include four visits at the Alfred Hospital, Melbourne, Australia. At visit 1, baseline measurement will be taken, including muscle sympathetic nerve activity (MSNA) and electrocardiogram (ECG). Participants will be randomised to the order in which they receive the placebo and HAMSA/B shake. Each intervention period will last 14 days, separated by a 20-day washout before participants cross over to the alternate treatment. At each visit, faecal, urine, and blood samples will be collected to investigate microbiome, cardiometabolic, renal, and immune profiles, respectively. Univariate and multivariate statistical analyses will be conducted to examine treatment effects and to identify correlations among microbiome, cardiometabolic, renal, and immune outcomes. DISCUSSION: This project's primary outcome is change in autonomic nervous system activity. Secondary outcomes include 24-h BP, gut microbiome composition, SCFA levels, immune cell profiles gastrointestinal transit time, quality of life, anxiety and depression symptoms, cognitive function, gut barrier integrity, and circulating micro- and nanoplastics. Findings from this study will reveal whether SCFAs reduce blood pressure by their influence on the autonomic nervous system. TRIAL REGISTRATION: This trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12625000557437).
引用
- Welathanthree M, Snelson M, Rim D, et al. Gut Regulated Associations of Neuronal Signalling in High Blood Pressure (GRAINS-BP): a double-blinded randomised crossover placebo-controlled trial. Trials. 2026. PMID: 42894232. doi:10.1186/s13063-026-09911-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。